JP2019530713A - 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 - Google Patents

腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 Download PDF

Info

Publication number
JP2019530713A
JP2019530713A JP2019519669A JP2019519669A JP2019530713A JP 2019530713 A JP2019530713 A JP 2019530713A JP 2019519669 A JP2019519669 A JP 2019519669A JP 2019519669 A JP2019519669 A JP 2019519669A JP 2019530713 A JP2019530713 A JP 2019530713A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
administration
day
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019519669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530713A5 (OSRAM
Inventor
ラドコ コマース，
ラドコ コマース，
アルヴィン シー，
アルヴィン シー，
Original Assignee
レトロフィン， インコーポレイテッド
レトロフィン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レトロフィン， インコーポレイテッド, レトロフィン， インコーポレイテッド filed Critical レトロフィン， インコーポレイテッド
Publication of JP2019530713A publication Critical patent/JP2019530713A/ja
Publication of JP2019530713A5 publication Critical patent/JP2019530713A5/ja
Priority to JP2022113880A priority Critical patent/JP2022141802A/ja
Priority to JP2022113881A priority patent/JP2022137245A/ja
Priority to JP2024225044A priority patent/JP2025060754A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019519669A 2016-10-13 2017-10-13 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物 Withdrawn JP2019530713A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022113880A JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113881A JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2024225044A JP2025060754A (ja) 2016-10-13 2024-12-20 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407860P 2016-10-13 2016-10-13
US62/407,860 2016-10-13
US201662423079P 2016-11-16 2016-11-16
US62/423,079 2016-11-16
PCT/US2017/056538 WO2018071784A1 (en) 2016-10-13 2017-10-13 Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022113880A Division JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113881A Division JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Publications (2)

Publication Number Publication Date
JP2019530713A true JP2019530713A (ja) 2019-10-24
JP2019530713A5 JP2019530713A5 (OSRAM) 2020-11-19

Family

ID=60191503

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019519669A Withdrawn JP2019530713A (ja) 2016-10-13 2017-10-13 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113881A Pending JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113880A Pending JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2024225044A Pending JP2025060754A (ja) 2016-10-13 2024-12-20 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022113881A Pending JP2022137245A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2022113880A Pending JP2022141802A (ja) 2016-10-13 2022-07-15 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物
JP2024225044A Pending JP2025060754A (ja) 2016-10-13 2024-12-20 腎臓疾患または障害を処置するためのビフェニルスルホンアミド化合物

Country Status (10)

Country Link
US (5) US20190262317A1 (OSRAM)
EP (1) EP3525784A1 (OSRAM)
JP (4) JP2019530713A (OSRAM)
KR (4) KR20190077348A (OSRAM)
CN (5) CN114788823A (OSRAM)
AU (3) AU2017341825B2 (OSRAM)
BR (1) BR112019007576A2 (OSRAM)
CA (1) CA3039819A1 (OSRAM)
MA (1) MA46524A (OSRAM)
WO (1) WO2018071784A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507739A (ja) * 2019-12-17 2023-02-27 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7524167B2 (ja) * 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
CN114126712A (zh) * 2018-12-21 2022-03-01 特拉维尔治疗公司 无定形司巴森坦（sparsentan）组合物
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
JP2023521169A (ja) * 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
WO2022246200A1 (en) 2021-05-21 2022-11-24 Travere Therapeutics, Inc. Methods of treating kidney diseases or disorders
KR20240051999A (ko) 2021-08-26 2024-04-22 상하이 한서 바이오메디컬 컴퍼니 리미티드 방향족 고리 함유 생물학적 길항제, 이의 제조 방법 및 용도
AR128112A1 (es) * 2021-12-28 2024-03-27 Alchemedicine Inc Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2024249509A1 (en) 2023-05-31 2024-12-05 Travere Therapeutics, Inc. Sparsentan for use in a method of treating iga-mediated diseases
WO2025064688A1 (en) 2023-09-20 2025-03-27 Travere Therapeutics, Inc. Sparsentan for treating immunoglobulin a nephropathy (igan)
CN118666826A (zh) * 2024-08-23 2024-09-20 成都臻拓医药科技有限公司 一种司帕生坦原料药的重结晶纯化方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
EP1237888B1 (en) 1999-12-15 2006-09-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
WO2010135350A2 (en) 2009-05-20 2010-11-25 Pharmacopeia, Llc Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist
US9719981B2 (en) * 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
LT3126330T (lt) * 2014-04-04 2019-04-25 Pfizer Inc. Bicikliniai kondensuoti heteroarilo arba arilo junginiai, ir jų panaudojimas kaip irak4 inhibitorių
JP7524167B2 (ja) 2018-10-04 2024-07-29 トラビア セラピューティクス， インコーポレイテッド Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012522058A (ja) * 2009-03-31 2012-09-20 リガンド・ファーマシューティカルズ・インコーポレイテッド 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AM J PHYSIOL REGUL INTEGR COMP PHYSIOL, vol. 310, JPN6021029020, March 2016 (2016-03-01), pages 877 - 884, ISSN: 0004731476 *
CURR HYPERTENS REP, vol. 17, JPN6021029017, 2015, pages 57, ISSN: 0004731478 *
INT HEART J, vol. 56, no. 6, JPN6021029019, 2015, pages 585 - 586, ISSN: 0004731477 *
KIDNEY INTERNATIONAL, vol. 86, JPN6021029016, 2014, pages 896 - 904, ISSN: 0004731479 *
医学のあゆみ, vol. 243, no. 9, JPN6021029014, 2012, pages 758 - 762, ISSN: 0004731481 *
日腎会誌, vol. 53, no. 2, JPN6022010127, 2011, pages 78 - 123, ISSN: 0004731482 *
臨床病理, vol. 61, no. 7, JPN6021029015, 2013, pages 616 - 621, ISSN: 0004731480 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507739A (ja) * 2019-12-17 2023-02-27 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
JP7624995B2 (ja) 2019-12-17 2025-01-31 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
JP2025060686A (ja) * 2019-12-17 2025-04-10 チヌーク セラピューティクス，インコーポレイテッド アトラセンタンによるｉｇａ腎症を治療する方法
WO2024101440A1 (ja) * 2022-11-11 2024-05-16 株式会社アークメディスン 化合物、エンドセリンａ受容体拮抗剤、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物

Also Published As

Publication number Publication date
KR20190077348A (ko) 2019-07-03
US20210196688A1 (en) 2021-07-01
US20200281901A1 (en) 2020-09-10
US20250325523A1 (en) 2025-10-23
AU2017341825B2 (en) 2023-06-01
CN116983302A (zh) 2023-11-03
AU2023219839A1 (en) 2023-09-07
CA3039819A1 (en) 2018-04-19
JP2022141802A (ja) 2022-09-29
KR20220132030A (ko) 2022-09-29
EP3525784A1 (en) 2019-08-21
JP2025060754A (ja) 2025-04-10
JP2022137245A (ja) 2022-09-21
AU2023219839B2 (en) 2025-08-21
CN117017985A (zh) 2023-11-10
US20250325522A1 (en) 2025-10-23
AU2017341825A1 (en) 2019-04-11
KR20230066644A (ko) 2023-05-16
US20190262317A1 (en) 2019-08-29
BR112019007576A2 (pt) 2019-07-02
KR102528435B1 (ko) 2023-05-03
CN117085013A (zh) 2023-11-21
WO2018071784A1 (en) 2018-04-19
AU2025271121A1 (en) 2025-12-18
KR20240162167A (ko) 2024-11-14
CN114788823A (zh) 2022-07-26
US10864197B2 (en) 2020-12-15
MA46524A (fr) 2019-08-21
CN110049764A (zh) 2019-07-23

Similar Documents

Publication Publication Date Title
US20250325522A1 (en) Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders
US20220048900A1 (en) Amorphous sparsentan compositions
US11207299B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
WO2022246200A1 (en) Methods of treating kidney diseases or disorders
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
WO2025064688A1 (en) Sparsentan for treating immunoglobulin a nephropathy (igan)
KR102902972B1 (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
BR122025008185A2 (pt) Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220725

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220726

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220728